Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Analysis of me-too drug approvals over time shows trends across therapy areas.
The companies hope that the US regulator approves patisiran and lorlatinib.
A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.